Advice
in the absence of a submission from the holder of the marketing authorisation:
perampanel (Fycompa®) is not recommended for use within NHSScotland.
Indication under review: for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice351KB (PDF)
Medicine details
- Medicine name:
- perampanel (Fycompa)
- SMC ID:
- SMC2218
- Indication:
For the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 August 2019